Dashboard
Discussions
Watchlists
Collections
Tools
More
Events
SIGN UP
SIGN IN
Sign in with Google
ENTITY
SMARTSCORE: 3.4/5
Dr Lal PathLabs Ltd (DLPL IN)
Watchlist
Contact IR
75
Analysis
Health Care
•
India
Dr. Lal PathLabs Limited operates clinical laboratories. The Company offers medical diagnostic, cardiology, radiology, pathology and imaging, health checkup, blood test, and customer care services. Dr. Lal PathLabs conducts its business in India.
more
Watchlist
Contact IR
All
Insights
Broker
Sponsored
Syndicated
Podcast
Buy side
Refresh
Focused
Suggested
bullish
•
Dr Lal PathLabs Ltd
•
17 Mar 2025 23:30
•
Broker
Dr. Lal Pathlabs: Focus on volume-led growth and margin. Maintain ADD
The company is focusing on innovation, including new wellness packages and high-end, super-specialty tests, with a focus on capturing prescription...
HDFC Securities
Follow
206 Views
Share
bullish
•
Dr Lal PathLabs Ltd
•
24 Oct 2024 14:21
Dr Lal PathLabs Ltd (DLPL IN): Volume Driven Topline Growth and Margin Improvement Continued in Q2
Dr Lal PathLabs reports 10% revenue growth in Q2, driven by volume, with bottomline surge outpacing revenue growth. The company has maintained 10%...
Tina Banerjee
Follow
353 Views
Share
bullish
•
Dr Lal PathLabs Ltd
•
02 Oct 2024 14:45
Dr Lal PathLabs Ltd (DLPL IN): Poised for Next Level of Growth Amid Easing Price Competition
Dr Lal PathLabs expects 10% revenue growth fueled by patient volume in FY25. The company is looking for small or mid-sized acquisitions in South...
Tina Banerjee
Follow
410 Views
Share
bullish
•
Cross Asset Strategy
•
24 Sep 2024 10:50
Indonesia Strategy - Caught in a Perfect Updraft?
Despite the JCI knocking on all-time highs, valuations continue to look attractive with prospects of a better 2H2024 and lower interest rates. Top...
Angus Mackintosh
Follow
525 Views
Share
bullish
•
Prodia
•
30 Mar 2023 23:49
Prodia (PRDA IJ) - Back to Core Testing
Prodia (PRDA IJ) FY2022 results saw declines in revenues and profits but from a COVID-high base and the numbers are now well-above 2019, with...
Angus Mackintosh
Follow
540 Views
Share
1
2
3
4
Next
Last
For Institutional Investors and Financial Services
For Corporate IR and Strategy
For Private Wealth Intermediaries
Pricing
Who We Are
Careers
FAQs
Research Provider Solutions
Syndicate your Publications
Compliance
Terms of Use
Privacy Policy
Press Kit
RSS Feeds
Request a Free Trial
Avail a Transition Account
Guest Posts on Smartkarma
Other Enquiries
Join TL;DR Community
Free Weekly Newsletters
Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.53.3
x